Nichole Tucker

"TAR-200 is a sort of a pretzel device. It's a novel drug delivery mechanism that's placed inside the bladder for sustained release of gemcitabine," explains Siamak Daneshmand, MD.

Patients in the trial received switch maintenance with darolutamide following prior taxane chemotherapy and at least 1 androgen-receptor pathway inhibitor.

The updated results were shared at the 2022 International Kidney Cancer Symposium.

Researchers hope to find synergistic effects with the combination of the ribosomal RNA synthesis inhibitor pidnarulex and the PARP inhibitor talazoparib.

The costimulatory bispecific antibody REGN5678 may alleviate resistance to immune checkpoint inhibition historically observed in prostate tumors.

“This is a new standard of care when managing metastatic bladder cancer patients,” says Joaquim Bellmunt, MD, PhD.

The benefit with darolutamide was observed, regardless of whether or not patients had prior local therapy.

The study specifically examined this precision medicine pathway in the context of frontline treatment selection between nivolumab with or without ipilimumab and a VEGFR tyrosine kinase inhibitor.

An analysis of the phase 2 TITAN-RCC trial found multiple immune cell factors associated with high rates of response to nivolumab/ipilimumab in advanced renal cell carcinoma.

Patients had received at least 1 novel hormonal agent and had non-progressive disease after subsequent treatment with taxane-based therapy.

Thomas Powles, MBBS, MRCP, MD, discusses where enfortumab vedotin fits in the bladder cancer treatment paradigm.

ARX517 is being explored in patients with prostate cancer and other PSMA-expressing solid tumors.

Results from a pooled analysis of frontline treatment in metastatic renal cell carcinoma provided early evidence of a differential overall survival benefit between patients with favorable-risk disease compared to patients with intermediate/poor-risk disease.